# Ovo Labs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ovo-labs

- Industry: Biotechnology
- Headquarters: Londonuu, UK
- Website: www.ovo-labs.com
- Total disclosed funding: $5M
- Latest round: Seed (Mar 5, 2025)
- Investors on record: 4

## About

Ovo Labs is a biotechnology company focused on creating innovative therapeutics to enhance egg quality and improve IVF success rates, targeting age-related fertility challenges.Founded in 2025 and based in London, UK, Ovo Labs specializes in developing therapeutics that improve egg quality. The company has raised GBP 4 million in Seed funding, attracting investors such as Creator Fund and LocalGlobe. The founder, with a history of entrepreneurial ventures, leads the company towards addressing fertility issues in women, especially those aged 35 and above. The company has plans for expanding its operations globally, particularly aimed at North America and Europe.Ovo Labs specializes in developing innovative therapeutics aimed at enhancing egg quality to improve the success rates of in vitro fertilization (IVF). The company is advancing three distinct egg rejuvenation therapeutics through preclinical development, designed to address the decline in fertility associated with aging. These therapeutics target chromosome segregation errors that occur as eggs mature, a significant factor in the failure of IVF cycles, particularly in women aged 35 and older. By harnessing advanced biological techniques, Ovo Labs aims to increase IVF success rates by 20-30% for women under 35 and by 3-5 times for those aged 35-45. The primary customer base includes fertility clinics and healthcare providers specializing in reproductive health, with products expected to have a presence in key markets such as North America, Europe, and parts of Asia, where infertility rates are notably high and demand for assisted reproductive technologies continues to grow.Ovo Labs operates primarily through a partnership model with fertility clinics and healthcare facilities, facilitating the integration of their therapeutics into existing IVF protocols. The revenue-generating transactions are structured around licensing agreements and collaborations, where clinics may pay for access to the therapeutics once they are commercially available. Specific pricing plans for these therapeutics are proprietary; however, they are likely aligned with standard industry practices for advanced medical treatments. The company's flagship products, which are positioned to transform IVF success rates, are anticipated to attract significant interest from clinics seeking to enhance their service offerings and improve patient outcomes. Overall, the revenue model reflects a direct relationship with healthcare providers, emphasizing a B2B approach tailored to the complexities of reproductive health solutions.In April 2025, Ovo Labs raised GBP 4 million in Seed funding co-led by new investor Creator Fund and LocalGlobe, with participation from other new investors Blue Wire Capital and Ahren Innovation Capital. The company will use the funding to advance its egg-quality therapeutics from preclinical development to clinical application, aiming to improve IVF success rates by addressing age-related infertility at its root. Plans include launching new therapeutics targeting assisted reproductive technologies and expanding operations into North America and Europe by 2026.

## Funding rounds

- Seed, Mar 5, 2025, $5M — Blue Wire Capital, LocalGlobe, Ahren Innovation Capital, Creator Fund

## Investors

- Blue Wire Capital (https://capitalatlas.ai/funds/blue-wire-capital) — Seed
- LocalGlobe (https://capitalatlas.ai/funds/localglobe) — Seed
- Ahren Innovation Capital (https://capitalatlas.ai/funds/ahren-innovation-capital) — Seed
- Creator Fund (https://capitalatlas.ai/funds/creator-fund) — Seed